The test is for early stage breast cancer patients to determine if the cancer will return over a 10 year span. If there is a high chance the cancer will come back, the patient is typically advised to go for chemotherapy. If there is a low chance of recurrence, the patient can typically avoid chemotherapy entirely. Every patient is classified as either low-risk or high-risk leaving.
In medicine, it is very rare to have a black-and-white answer given by a test for each and every patient. EndoPredict delivers on this promise.
EndoPredict has recently undergone a number of upgrades. Now, in addition to the information above, EndoPredict also gives the exact percentage benefit of chemotherapy and endocrine therapy.
For a 15 year span.
This enables EndoPredict to be the only test to answer three critical clinical questions and do so with a high level of accuracy.
2. What is the patient’s benefit from chemotherapy?
3. Who is likely to benefit from Endocrine therapy over a longer duration?